Johnson & Johnson topped Wall Street expectations for the second quarter, reporting revenue of $23.74 billion and adjusted earnings of $2.77 a share. Sales grew 5.8 % from a year earlier and came in almost $900 million above the analyst consensus, while profit exceeded estimates by nine cents. Buoyed by the performance, the New Brunswick-based drug and device maker raised its full-year outlook. It now projects 2025 sales of $93.2 billion to $93.6 billion, up from $91 billion to $91.8 billion, and lifted its adjusted earnings forecast to $10.80-$10.90 a share. Management also halved its estimate of tariff-related costs for the year to about $200 million, citing a pause in new levies and internal cost controls. On the product front, pharmaceutical revenue topped $15 billion for the first time. Flagship blood-cancer drug Darzalex generated $3.54 billion, comfortably beating expectations and offsetting a 43 % slide in sales of psoriasis therapy Stelara following the loss of U.S. market exclusivity. The MedTech division, helped by cardiovascular devices and wound-closure products, delivered operational sales growth of 6.1 % to $8.54 billion. Investors welcomed the beat-and-raise quarter: Johnson & Johnson shares gained almost 6 % in early New York trading, kick-starting the healthcare earnings season on a positive note.